Add-Aspirin Trial to Assess the Anti-Cancer Effects of Aspirin on 11,000 Participants Across Three Countries, Including Republic of Ireland

Published Thursday, October 18th, 2018 at 15:35 pm

The Mater Private Hospital is participating in the recruitment for the Add-Aspirin Trial. This large international trial will investigate if taking aspirin daily can prevent the spreading or relapse of early stage cancer after treatment. The trials are taking place in the UK, India and The Republic of Ireland, with 11,000 participants from the three countries. 

In Ireland, 300 volunteers who have previously experienced or have started treatment for early stage cancer will join the trial. The study will include patients with cancer from several areas such as breast, oesophagus, stomach, colon, rectum and prostate. Cancer Trials Ireland will be co-ordinating the trials with support and funding from the Health Research Board and The Irish Cancer Society. 


The Mater Private Hospital will be a participating recruitment centre for this trial along with many others in Ireland such as the Mater Misericordiae University Hospital, Beaumont, Tallaght Hospital,  St. Vincent’s University Hospital, Bon Secours Hospital Cork, Cork University Hospital, Sligo University Hospital, University Hospital Galway and University Hospital Limerick. 

Aspirin is widely used as a painkiller and in the prevention and treatment of heart and stroke disease. In previous studies conducted, looking at the effect of aspirin on heart disease and stroke, fewer people appeared to develop cancer and for those who did, it appeared less likely to spread. 
These trials do not provide enough supporting evidence, as they were not specifically designed to investigate the impact of aspirin on cancer, but rather the drug’s effect on cardiovascular disease. 

The Add-Aspirin trial aims to provide scientific evidence that taking aspirin daily for five years can prevent a patient’s cancer returning and prolong the life of those who have received standard therapy including surgery, chemotherapy and radiotherapy. 

If this trial is successful, it is hoped Aspirin will improve health outcomes for several of the most common cancers, greatly impacting human health globally. Aspirin is also a low-cost drug that is generally safe with well-known side effects. The generic drug is available worldwide and accessible in low resource countries that have rising cancer rates. 

For more information about this trial, visit